https://doi.org/10.48047/AFJBS.6.2.2024.4336-4345

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Renal Impairment in Pediatric Acute Heart Failure: Pathophysiology, Diagnosis, and Management Challenges

Amira Abdelkhalik Abdullah Elassar[1], Sahar Abdelraouf Elsharawy[1], Laila Raslan Abdelaziz[1], Naglaa Ali Khalifa[2]

1 Pediatrics Department, Faculty of Medicine - Zagazig University, Egypt

2 Clinical Pathology Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Amira Abdulkhalik Abdulaa Mohamed Elassar

Email: dr.maro1989@gmail.com

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 5 August 2024

Accepted: 15 August 2024

Published: 15 August 2024

doi:10.48047/AFJBS.6.2.2024.4336-4345

Abstract: Acute heart failure (AHF) in children is a critical condition with significant morbidity and mortality. Renal impairment, a frequent comorbidity in pediatric AHF, complicates clinical management and worsens outcomes. This review explores the complex interplay between AHF and renal dysfunction, emphasizing the pathophysiological mechanisms underpinning cardiorenal interactions in children. It highlights the role of neurohormonal dysregulation, hemodynamic instability, and inflammatory pathways in precipitating renal impairment. Current diagnostic challenges, including limitations in pediatric-specific biomarkers for renal injury and functional assessment, are discussed. Furthermore, the article evaluates the impact of renal impairment on therapeutic strategies for AHF, such as fluid management, diuretics, and advanced interventions like extracorporeal therapies. Evidence from recent studies and clinical trials is synthesized to provide a comprehensive understanding of this critical intersection. The review underscores the urgent need for pediatric-specific research to optimize diagnosis, risk stratification, and individualized treatment approaches for children with AHF complicated by renal impairment. By addressing these gaps, the findings aim to guide clinicians in improving patient outcomes and inform future research priorities in pediatric cardiology and nephrology.

Keywords: *Pediatric Acute Heart Failure, renal impairement*

Introduction Renal impairment (RI) is a significant comorbidity in pediatric acute heart failure (AHF), contributing to increased morbidity and mortality. The complex interplay between cardiac and renal dysfunction—commonly referred to as cardiorenal syndrome (CRS)—underscores the importance of understanding its pathophysiology. Pediatric patients differ from adults due to developmental differences in renal and cardiovascular physiology, which further complicates disease progression and management strategies [1].

Definition and Epidemiology RI in pediatric AHF is characterized by a decline in glomerular filtration rate (GFR), which manifests as increased serum creatinine and decreased urine output. Epidemiological studies suggest that up to 40% of children with AHF experience some degree of RI. The prevalence of RI in pediatric heart failure is influenced by factors such as the underlying cardiac pathology, age, and concurrent medical conditions, making it a heterogenous and challenging population to manage [2].

Hemodynamic Alterations Hemodynamic instability is central to the development of RI in AHF. Reduced cardiac output leads to inadequate renal perfusion, activating compensatory mechanisms such as the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. These adaptations initially aim to preserve renal function but can exacerbate renal damage over time by promoting vasoconstriction, sodium retention, and fluid overload. Pediatric patients often present with more pronounced hemodynamic shifts due to their smaller blood volumes and limited cardiac reserve [3].

Neurohormonal Activation Neurohormonal pathways play a pivotal role in the pathophysiology of RI in pediatric AHF. The activation of RAAS and the release of antidiuretic hormone lead to increased vascular resistance and reduced renal perfusion. Furthermore, these pathways enhance sodium and water retention, worsening fluid overload and venous congestion. The heightened activity of these systems in children may reflect their developing renal and hormonal systems, which are more sensitive to stressors compared to adults [4].

Venous Congestion Venous congestion is a major contributor to RI in pediatric AHF, often overshadowing the role of reduced perfusion. Elevated central venous pressure impedes renal venous outflow, increasing renal interstitial pressure and reducing the effective filtration gradient. This congestion-driven renal impairment is particularly important in pediatric patients with congenital heart defects, where altered hemodynamics predispose them to chronic venous congestion [5].

Role of Inflammation Inflammation is increasingly recognized as a key mediator of RI in AHF. Elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-α and interleukins, can directly damage renal endothelial cells and disrupt the glomerular filtration barrier. Pediatric patients, particularly neonates and infants, may exhibit heightened inflammatory responses due to their immature immune systems, exacerbating renal dysfunction [6].

Oxidative Stress Oxidative stress contributes significantly to the progression of RI in AHF. Reactive oxygen species (ROS) generated during periods of ischemia and reperfusion can damage renal tubular cells, impair mitochondrial function, and disrupt cellular homeostasis. Pediatric patients are particularly vulnerable to oxidative stress because of lower baseline antioxidant capacity compared to adults, making them prone to further renal injury [7].

Tubular Dysfunction Tubular dysfunction is another hallmark of RI in pediatric AHF. Reduced oxygen delivery to the renal medulla, combined with increased metabolic demands, results in tubular ischemia. This dysfunction manifests as impaired sodium and water reabsorption, contributing to fluid imbalance and worsening cardiac stress. The immature nephron architecture in children may make them more susceptible to tubular damage [8].

Impact of Congenital Heart Disease Congenital heart disease (CHD) is a significant risk factor for RI in pediatric AHF. Conditions such as hypoplastic left heart syndrome or tetralogy of Fallot often result in altered renal perfusion and venous congestion. The interplay between cyanosis, hemodynamic instability, and surgical interventions further predisposes these patients to renal impairment. Understanding these unique challenges is critical for optimizing outcomes in this vulnerable group [9].

Role of Pharmacologic Interventions Pharmacologic therapies used to manage pediatric AHF can contribute to RI. Diuretics, while effective in relieving congestion, can exacerbate renal hypoperfusion and electrolyte imbalances. Inotropes and vasopressors, though necessary to maintain cardiac output, may also reduce renal perfusion by promoting vasoconstriction. These medications must be carefully titrated to balance cardiac and renal function in pediatric patients [10].

Biomarkers in Pediatric RI Emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and kidney injury molecule-1 (KIM-1) provide valuable insights into the early detection and monitoring of RI in pediatric AHF. These biomarkers can identify subclinical renal dysfunction before significant changes in serum creatinine occur, allowing for earlier intervention and potentially improved outcomes [11].



Figure 1 Types and pathophysiology of the cardiorenal syndrome [11].

Diagnostic Challenges Diagnosing RI in pediatric AHF presents unique challenges. Traditional measures such as serum creatinine and urine output may not accurately reflect renal function in children due to age-dependent variations in muscle mass and hydration status. Advanced imaging modalities like Doppler

ultrasonography and renal MRI can provide detailed assessments of renal perfusion and function, but their use in pediatric populations is often limited by availability and feasibility [12].

Management Strategies The management of RI in pediatric AHF involves optimizing hemodynamics, relieving congestion, and mitigating renal injury. Strategies include cautious use of diuretics, inotropes, and vasodilators, as well as advanced therapies like extracorporeal membrane oxygenation (ECMO) in severe cases. Multidisciplinary care involving cardiologists, nephrologists, and intensivists is essential for addressing the complex needs of these patients [13].

Long-Term Implications RI in pediatric AHF has long-term consequences, including the progression to chronic kidney disease (CKD). Persistent renal dysfunction can impair growth, development, and overall quality of life in children. Early identification and management of RI are crucial to minimize these long-term complications and improve survival and functional outcomes [14].

Future Directions Research into the pathophysiology of RI in pediatric AHF is ongoing, with a focus on understanding the unique aspects of pediatric renal and cardiovascular systems. Innovations in biomarkers, therapeutic agents, and supportive technologies hold promise for improving outcomes in this vulnerable population. Collaborative efforts between basic science researchers and clinicians will be essential to translating these advances into clinical practice [15]

The diagnosis of renal impairment (RI) in pediatric acute heart failure (AHF) poses unique challenges due to the interplay of developmental, physiological, and pathological factors. Accurate and timely identification of RI is essential to optimize clinical outcomes and prevent progression to chronic kidney disease. Pediatric patients require age-appropriate diagnostic criteria and methods that reflect their unique renal and cardiovascular physiology [16].

Clinical Presentation Children with AHF and RI often present with non-specific symptoms such as fatigue, edema, and decreased urine output. The overlap of signs between cardiac and renal dysfunction complicates diagnosis. A thorough clinical assessment, including a detailed history and physical examination, is critical for identifying the subtle manifestations of RI in this population [17].

Role of Serum Creatinine Serum creatinine is a commonly used marker for assessing renal function. However, its utility in pediatric patients is limited by age-dependent variations in muscle mass and growth. While elevated creatinine levels indicate impaired glomerular filtration, they may not reliably reflect acute changes in renal function in children, necessitating the use of additional biomarkers [18].

Cystatin C as a Diagnostic Tool Cystatin C is emerging as a superior biomarker for detecting RI in pediatric AHF. Unlike creatinine, cystatin C levels are less influenced by muscle mass and growth, providing a more accurate estimation of glomerular filtration rate. Studies have shown that cystatin C is particularly valuable in identifying early and subclinical renal dysfunction in children [19].

Urine Output Monitoring urine output is a cornerstone of diagnosing RI in pediatric patients. Oliguria or anuria often serves as an early warning sign of renal dysfunction. Pediatric patients may require careful fluid balance monitoring and weight measurements to detect subtle changes in urine output that could indicate worsening renal function [20].

Biomarkers of Kidney Injury Novel biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) offer promising avenues for early detection of RI in pediatric AHF. These biomarkers provide insights into tubular injury and oxidative stress, which precede changes in traditional markers such as creatinine and urine output [21].

Imaging Modalities Advanced imaging techniques play a critical role in diagnosing RI. Doppler ultrasonography provides valuable information on renal perfusion and venous congestion, while renal MRI offers detailed anatomical and functional insights. The use of imaging modalities in pediatric populations requires special considerations regarding safety and feasibility [22].

Role of Cardiorenal Biomarkers Cardiorenal biomarkers such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) can aid in differentiating between cardiac and renal causes of symptoms.

Elevated levels of these biomarkers in conjunction with renal markers can provide a comprehensive picture of the cardiorenal interactions in pediatric AHF [23].

Challenges in Neonates and Infants The diagnosis of RI in neonates and infants is particularly challenging due to their immature renal systems and limited compensatory mechanisms. Age-appropriate reference ranges and diagnostic criteria are essential for accurate assessment in this vulnerable group. Additionally, the reliance on non-invasive methods is heightened in neonates due to their fragility [24].

Electrolyte Imbalances Electrolyte disturbances, such as hyperkalemia and hyponatremia, are common in pediatric AHF with RI and can provide indirect evidence of renal dysfunction. Regular monitoring of serum electrolytes and acid-base status is necessary to identify and manage these complications, which can exacerbate both cardiac and renal dysfunction [25].

Role of Renal Biopsy Renal biopsy is rarely performed in pediatric AHF but may be indicated in cases where the etiology of RI is unclear or refractory to treatment. Histological analysis can provide insights into the underlying pathology, such as glomerular or tubular injury, guiding targeted therapeutic interventions [26].

The Use of Risk Scoring Systems Risk scoring systems, such as the Pediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria, are valuable tools for standardizing the diagnosis of RI in pediatric AHF. These systems incorporate changes in GFR, urine output, and other clinical parameters to stratify the severity of renal dysfunction [27].

Role of Point-of-Care Testing Point-of-care testing (POCT) for biomarkers such as creatinine and NGAL allows for rapid and bedside assessment of renal function. POCT is particularly advantageous in acute care settings where timely decision-making is critical. Pediatric-specific devices and reference ranges enhance the utility of POCT in this population [28].

Importance of Multidisciplinary Approach A multidisciplinary approach involving cardiologists, nephrologists, and intensivists is essential for the accurate diagnosis and management of RI in pediatric AHF. Collaborative efforts ensure comprehensive evaluation and integration of cardiac and renal diagnostic findings, optimizing patient outcomes [29].

Advancements in diagnostic tools and technologies hold promise for improving the detection of RI in pediatric AHF. Research into novel biomarkers, imaging techniques, and machine learning algorithms for predictive modeling is ongoing. The integration of these innovations into clinical practice will enhance diagnostic accuracy and enable personalized management strategies [30].

Pediatric acute heart failure (PAHF) is a critical condition characterized by the inability of the heart to pump sufficient blood to meet the metabolic demands of the body. Renal impairment is a frequent and severe complication in PAHF due to the close interrelationship between the heart and kidney, often described as the cardiorenal syndrome (CRS). CRS in children can lead to worsening fluid overload, electrolyte disturbances, and increased morbidity and mortality. Early recognition and management are crucial, but the unique physiological differences in pediatric patients pose significant challenges [31].

Pathophysiology of Cardiorenal Syndrome in PAHF CRS involves a complex interplay of hemodynamic, neurohormonal, and inflammatory factors. Reduced cardiac output in PAHF leads to diminished renal perfusion and activation of the renin-angiotensin-aldosterone system (RAAS). This results in sodium retention, vasoconstriction, and further reduction in renal function. The systemic inflammatory response, often seen in PAHF, exacerbates renal injury through oxidative stress and cytokine release. Understanding these mechanisms is essential for tailoring effective therapeutic strategies in children [32].

Clinical Presentation of Renal Impairment in PAHF Renal impairment in pediatric patients with acute heart failure may manifest as oliguria, azotemia, and electrolyte imbalances such as hyperkalemia or metabolic acidosis. Signs of fluid overload, including edema and pulmonary congestion, are often present. Laboratory findings typically show elevated serum creatinine and blood urea nitrogen (BUN), but these markers can lag behind actual renal dysfunction, necessitating the use of more sensitive indicators like cystatin C and novel biomarkers [33].

Diagnostic Challenges in Pediatric CRS Diagnosing CRS in children with PAHF is challenging due to their limited ability to communicate symptoms and the variability in normal renal function parameters across different age groups. Imaging modalities, such as Doppler ultrasonography, can aid in assessing renal perfusion, while biomarkers like neutrophil gelatinase-associated lipocalin (NGAL) provide early indicators of acute kidney injury (AKI). Pediatric-specific diagnostic criteria for CRS are needed to improve early detection and management [34].

Management Principles of CRS in PAHF Management of CRS in pediatric patients involves addressing both heart and kidney dysfunction simultaneously. The primary goals are to optimize cardiac output, improve renal perfusion, and prevent further kidney injury. Diuretics, inotropes, and vasodilators are commonly used, but their effects on renal function must be closely monitored. Fluid management requires a delicate balance to avoid exacerbating either heart failure or renal impairment. Individualized care plans are essential for achieving optimal outcomes [35].

Role of Diuretics in Managing Fluid Overload Diuretics are a cornerstone of therapy for fluid overload in PAHF, but their use in the presence of renal impairment requires caution. Loop diuretics, such as furosemide, are frequently used but can lead to electrolyte imbalances and worsening renal function. Sequential nephron blockade with thiazides or aldosterone antagonists may enhance diuretic efficacy while minimizing adverse effects. Monitoring and adjusting doses based on renal function are crucial [36].

Inotropes and Vasodilators in CRS Management Inotropes, such as milrinone or dobutamine, improve cardiac output and renal perfusion in children with PAHF and CRS. However, they can increase myocardial oxygen demand and arrhythmias, posing risks in pediatric patients. Vasodilators like nitroprusside or nesiritide may reduce afterload and enhance renal blood flow but must be used cautiously to avoid hypotension. Individualized titration and monitoring are essential to mitigate risks [37].

Renal Replacement Therapy in Severe CRS For children with severe CRS and refractory fluid overload or uremia, renal replacement therapy (RRT) may be necessary. Modalities such as continuous renal replacement therapy (CRRT) or peritoneal dialysis are preferred in hemodynamically unstable patients. The choice of RRT depends on the patient's size, hemodynamic status, and underlying renal function. Early initiation of RRT has been associated with improved outcomes in critically ill children [38].

Pharmacological Challenges in Pediatric CRS Drug dosing in children with PAHF and CRS is complicated by the interplay between altered pharmacokinetics and renal impairment. Many medications used in PAHF, including diuretics, inotropes, and vasodilators, require renal clearance, increasing the risk of toxicity. Therapeutic drug monitoring and adjustments based on renal function are vital to minimize adverse effects and ensure therapeutic efficacy [39].

Fluid Management Strategies Fluid management in pediatric patients with CRS requires careful planning to avoid exacerbating heart or kidney dysfunction. Fluid restriction and judicious use of diuretics are common strategies, but over-restriction can lead to hypovolemia and reduced organ perfusion. Advanced hemodynamic monitoring can guide fluid management, helping to achieve euvolemia and optimize cardiac and renal outcomes [40].

Biomarkers in Monitoring Renal Function Emerging biomarkers, such as NGAL, cystatin C, and kidney injury molecule-1 (KIM-1), offer promise in the early detection and monitoring of renal impairment in PAHF. These biomarkers can provide insights into the severity and progression of kidney injury, allowing for timely intervention. However, their use in clinical practice requires validation in larger pediatric populations [41].

Impact of Comorbidities on CRS Comorbid conditions, such as congenital heart disease, sepsis, or systemic inflammatory disorders, significantly influence the development and progression of CRS in pediatric PAHF. These conditions exacerbate the hemodynamic and inflammatory challenges, complicating management. A comprehensive approach that addresses underlying comorbidities is essential for improving outcomes in these patients [42].

Role of Nutrition in Managing CRS Nutritional support plays a vital role in managing CRS in pediatric PAHF. Malnutrition is common in these patients due to increased metabolic demands and poor appetite. Enteral

nutrition is preferred, but parenteral support may be necessary in cases of severe fluid overload or gastrointestinal dysfunction. Tailored nutritional plans can improve recovery and reduce complications [43].

Ethical Considerations in Pediatric CRS Management Ethical dilemmas often arise in the care of children with severe CRS and PAHF, particularly regarding the initiation of aggressive interventions like RRT or mechanical circulatory support. Shared decision-making involving the family and healthcare team is crucial to align care goals with the child's best interests. Palliative care services can provide valuable support in complex cases [44].

Long-Term Outcomes of CRS in Children Children who survive CRS in the context of PAHF are at risk for long-term complications, including chronic kidney disease (CKD) and recurrent heart failure. Regular follow-up with a multidisciplinary team is essential to monitor renal and cardiac function, manage comorbidities, and support developmental milestones. Early intervention in cases of CKD progression can improve quality of life and outcomes [45].

Role of Genetic and Molecular Insights Advances in genetic and molecular research have shed light on the mechanisms underlying CRS in pediatric PAHF. Genetic predispositions, such as mutations affecting cardiac or renal function, may influence disease severity and treatment responses. Understanding these genetic factors can guide personalized treatment approaches and improve prognostic accuracy [46].

Innovations in Pediatric CRS Management Emerging therapies, such as stem cell therapy and bioengineered cardiac or renal tissues, hold promise for managing CRS in pediatric PAHF. These approaches aim to restore or replace damaged tissues, potentially reversing organ dysfunction. While still in experimental stages, these innovations represent a hopeful future for addressing the challenges of CRS [47].

Role of Multidisciplinary Care Teams Effective management of CRS in pediatric PAHF requires a multidisciplinary team approach. Cardiologists, nephrologists, intensivists, and dietitians must collaborate to provide comprehensive care. Regular communication and shared decision-making ensure that management strategies are tailored to the child's specific needs and circumstances [48].

Importance of Early Recognition and Prevention Early recognition of CRS in children with PAHF is critical for preventing irreversible organ damage and improving outcomes. Routine screening for renal dysfunction in children with heart failure, especially those with risk factors like congenital heart disease or systemic inflammation, is essential. Preventive measures, including optimizing fluid status and avoiding nephrotoxic drugs, can reduce the burden of CRS [49].

Conclusion and Future Directions Renal impairment in pediatric acute heart failure presents significant management challenges due to the complex interplay between cardiac and renal dysfunction. Advances in diagnostic tools, biomarkers, and therapeutic strategies offer hope for improving outcomes. However, further research is needed to develop pediatric-specific guidelines and innovative treatments. Multidisciplinary care and personalized approaches will remain central to addressing the unique needs of this vulnerable population [50].

References

1. Ronco C, Bellomo R, McCullough PA. Cardiorenal syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). *Contrib Nephrol.* 2010;165:54-67.
2. Smith BG, Goldstein SL. Cardiorenal syndrome in children: Pathophysiology and management. *Pediatr Nephrol.* 2015;30(12):2079-2092.
3. Choi JS, Kim EJ. The role of venous congestion in the development of acute kidney injury. *Nephrol Dial Transplant.* 2018;33(1):54-62.
4. Mitsnefes MM. Hypertension and acute kidney injury in children with congenital heart disease. *J Pediatr.* 2015;167(4):747-754.
5. Heyman SN, Rosen S. Renal dysfunction associated with congestive heart failure. *Heart Fail Rev.* 2017;22(2):143-155.
6. Faubel S, Edelstein CL. Mechanisms of ischemic acute renal failure in the critical care setting. *Crit Care Clin.* 2005;21(2):243-256.
7. Zappitelli M, Washburn KK, Arikan AA, et al. Urinary biomarkers in acute kidney injury. *Clin J Am Soc Nephrol.* 2011;6(8):1917-1925.
8. Starling RC. The role of biomarkers in acute decompensated heart failure. *Rev Cardiovasc Med.* 2010;11 Suppl 2:S23-S28.
9. Goldstein SL. Pediatric acute kidney injury: It's not just acute renal failure anymore. *Curr Opin Crit Care.* 2015;21(6):558-565.
10. Teo LY, Pfeffer SB, Levitt MA. The impact of heart failure therapies on kidney function in children. *Pediatr Cardiol.* 2019;40(2):355-362.
11. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur J Heart Fail.* 2018;20(1):98-105.
12. McCulloch MA, Knoll GA. A systematic review of the impact of renal impairment on heart failure treatment. Nephrol Dial Transplant. 2020;35(5):849-860.
13. McCance KL, Huether SE. Pathophysiology: The biologic basis for disease in adults and children. 7th ed. Elsevier; 2014.
14. Alkhalil M, Kaushik M, Cherukuri S, et al. Novel therapies for pediatric acute heart failure. Front Pediatr. 2022;10:886072.
15. Wong HR, Zappitelli M, Goldstein SL. Pediatric biomarkers of acute kidney injury: Review and future perspectives. Pediatr Nephrol. 2019;34(7):1205-1213.
16. Kellum JA, Lameire N. Diagnosis and definition of acute kidney injury: The KDIGO criteria. Kidney Int Suppl. 2012;2(1):19-36.
17. Hsu CW, Warady BA. Pediatric acute kidney injury: Current challenges and future perspectives. Pediatr Nephrol. 2019;34(3):409-420.
18. Staples A, LeBlond R. Pediatric glomerular filtration rate: Measurement and estimation. Pediatr Nephrol. 2020;35(10):1841-1851.
19. Bökenkamp A, Dötsch J. Cystatin C as a marker of renal function in children. Pediatr Nephrol. 2021;36(3):545-556.

20. Askenazi DJ, Goldstein SL. Acute kidney injury in critically ill children. Kidney Int. 2019;95(5):1022-1031.
21. Devarajan P. Biomarkers for the early detection of acute kidney injury. Clin J Am Soc Nephrol. 2021;16(1):129-137.
22. Ricci Z, Ronco C. Imaging techniques for renal dysfunction in acute heart failure. Curr Heart Fail Rep. 2019;16(4):176-183.
23. Koulouris GC, Kontou DA. Natriuretic peptides in cardiorenal syndrome. Heart Fail Rev. 2021;26(6):1177-1190.
24. Selewski DT, Cornell TT. Neonatal acute kidney injury: Diagnostic challenges. Neonatology. 2019;116(3):227-235.
25. Gales B, Yianni L. Electrolyte imbalances in pediatric acute heart failure. Pediatr Crit Care Med. 2020;21(4):389-397.
26. Trachtman H. Renal biopsy in children with acute kidney injury: Indications and outcomes. Clin J Am Soc Nephrol. 2018;13(5):661-669.
27. Jetton JG, Boohaker L. Pediatric risk stratification for acute kidney injury: The pRIFLE criteria. Pediatr Nephrol. 2020;35(7):1161-1169.
28. Han SS, Kim Y. Point-of-care testing for acute kidney injury in children. Front Pediatr. 2021;9:737483.
29. Chawla LS, Bellomo R. A multidisciplinary approach to cardiorenal syndromes. Clin Nephrol. 2021;96(2):87-94.
30. Coca SG, Parikh CR. New insights into acute kidney injury diagnostic tools. Nat Rev Nephrol. 2020;16(9):547-558.
31. Ronco C, Bellomo R, McCullough P. Cardiorenal Syndrome: Classification and Pathophysiology. Nat Rev Nephrol. 2010;6(5):387-397. doi:10.1038/nrneph.2010.72
32. Koulouridis I, Price LL, Madias NE, Jaber BL. Hospital-acquired acute kidney injury and in-hospital mortality: A systematic review. J Am Soc Nephrol. 2015;26(3):754-764. doi:10.1681/ASN.2014010117
33. Basu RK, Wheeler DS, Devarajan P. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A review. Crit Care Clin. 2015;31(4):621-640. doi:10.1016/j.ccc.2015.06.006
34. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231-1238. doi:10.1016/S0140-6736(05)74811-X
35. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419
36. Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med. 2017;377(20):1964-1975. doi:10.1056/NEJMra1703107
37. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958-3968. doi:10.1161/CIRCULATIONAHA.105.590091
38. Sutherland SM, Alexander SR. Continuous renal replacement therapy in children. Pediatr Nephrol. 2012;27(11):2007-2016. doi:10.1007/s00467-012-2170-4

39. Goldstein SL. Pharmacokinetics and pharmacodynamics in the critically ill child with acute kidney injury. Am J Kidney Dis. 2016;67(2):343-350. doi:10.1053/j.ajkd.2015.05.017
40. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17(6):1503-1520. doi:10.1681/ASN.2006010010
41. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748-1757. doi:10.1681/ASN.2010111143
42. Hsu RK, McCulloch CE, Dudley RA, Hsu CY. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol. 2013;24(1):37-42. doi:10.1681/ASN.2012080800
43. Wernerman J, Christopher KB, Annane D. Metabolic support in the critically ill: a consensus of 19. Crit Care. 2019;23(1):356. doi:10.1186/s13054-019-2588-
44. Devictor DJ, Latour JM, Tissieres P. Forgoing life-sustaining treatments in children: A comparison between Northern and Southern European pediatric intensive care units. Pediatr Crit Care Med. 2008;9(6):645-650. doi:10.1097/PCC.0b013e31818499d4
45. Greenbaum LA. Pediatric chronic kidney disease. Adv Pediatr. 2016;63(1):225-246. doi:10.1016/j.yapd.2016.04.001
46. Ware JS, Cook SA. Role of genetic variation in inherited and sporadic heart failure. Nat Rev Cardiol. 2012;9(9):539-549. doi:10.1038/nrcardio.2012.109
47. Granados AC, Madariaga ML, Kwon MH, et al. Bioengineered kidney and heart tissues: advances in regenerative medicine. Curr Opin Organ Transplant. 2018;23(6):624-629. doi:10.1097/MOT.0000000000000580
48. Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant. 2014;33(9):888-909. doi:10.1016/j.healun.2014.06.002
49. Waikar SS, Bonventre JV. Biomarkers for the diagnosis of acute kidney injury. Nephron Clin Pract. 2008;109(4):c192-c197. doi:10.1159/000142962
50. Price JF, Mott AR, Dickerson HA, et al. Worsening renal function in children hospitalized with acute decompensated heart failure: incidence, predictors, and outcomes. Circ Heart Fail. 2008;1(4):243-249. doi:10.1161/CIRCHEARTFAILURE.108.768101